Newswise, a news release and distribution service, hosted a live expert panel where participants discussed progress with COVID-19 vaccines and drug trials, as well as the epidemiology of the rising rate of COVID-19 cases in the United States.
Coriell Life Sciences’ Jeffrey Shaman notes, “Pharmacogenomics is not a silver bullet. It’s a helping hand for doctors to help zero in on treatment options. We’re now leveraging PGx to offer a variety of COVID-related services, including data interpretation and reporting services for SARS-CoV-2 detection and precision prescribing for COVID-19 treatment through genetics. CLS’ medication safety pharmacogenomics report delivers measurable benefits, including potentially quicker recovery, reduced healthcare costs, and simplified decision-making.”
View the full panel and read the complete transcript here: https://bit.ly/NewswiseExpertPanel
Dr. Edward Jones-Lopez: Assistant Professor & Infectious Diseases Specialist at Keck Medicine of USC & Investigator on the AstraZenea vaccine trial.
Perry N. Halkitis, Ph.D., MS, MPH: Dean of the Rutgers School of Public Health.
Dr. Stephen Spector: Professor, Pediatrics at UC San Diego & PI on the UCSD arm of the Moderna trial.
Sean Diehl, Ph.D.: Associate Professor at The University of Vermont Larner College of Medicine. Dr. Diehl found that the level of antibodies correlated with disease severity in a recent study.
Robert Salata, MD: Infectious Disease Specialist and Chairman of the Department of Medicine at University Hospitals Cleveland Medical Center and Participating in the study of the Phase 2/3 global study by Pfizer, Inc.
Shobha Swaminathan, MD: Associate Professor and the principal investigator for the Moderna trial at the Rutgers New Jersey Medical School.
Jeffrey A. Shaman, PhD: MS Chief Science Officer at Coriell Life Sciences.